# Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer

> **NCT04742075** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nordic Society of Gynaecological Oncology - Clinical Trials Unit** · enrollment: 188 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib + durvalumab + UV1

## Key facts

- **NCT ID:** NCT04742075
- **Lead sponsor:** Nordic Society of Gynaecological Oncology - Clinical Trials Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-15
- **Primary completion:** 2026-05-01
- **Final completion:** 2030-12-31
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04742075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04742075, "Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04742075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*